Radiation Therapy Enhances Outcomes for NSCLC Patients Treated with Nivolumab - Top-Institutions - MDSpire

Radiation Therapy Enhances Outcomes for NSCLC Patients Treated with Nivolumab

  • By

  • Seray Saray

  • Berke Engin

  • Ahmet Kadıoğlu

  • Mustafa Akın

  • Hüseyin Kanmaz

  • Yakup İriağaç

  • February 26, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Medical Oncology
    • Radiation Oncology
    • Immunotherapy

  • #2

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Medical Oncology
    • Radiation Oncology
    • Translational Research

  • #3

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Medical Oncology
    • Immunotherapy
    • Radiation Oncology

  • #4

    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

    Baltimore, MD

    Key Differentiators

    • Medical Oncology
    • Radiation Oncology
    • Cancer Immunology

  • #5

    University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center
    University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center

    San Francisco, CA

    Key Differentiators

    • Medical Oncology
    • Radiation Oncology
    • Immunotherapy

Original Source(s)

Radiation Therapy Enhances Outcomes for NSCLC Patients Treated with Nivolumab

  • by Seray Saray, Berke Engin, Ahmet Kadıoğlu, Mustafa Akın, Hüseyin Kanmaz, Yakup İriağaç

  • February 26, 2026

Related Content

HHLA2 as an emerging immune checkpoint in lung cancer: linking EGFR signaling, macrophage polarization, and CD8+ T-cell metabolic suppression

Case Report: Contrast-enhanced ultrasonography for evaluating a newly detected contralateral pulmonary lesion during non-small cell lung cancer chemoimmunotherapy

Case report: complete pathologic response to neoadjuvant ensartinib in locally advanced, ALK-positive lung squamous cell carcinoma